December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
June 2025 in “British Journal of Dermatology” Certain hair and scalp features can predict the severity of alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
19 citations
,
October 2019 in “Clinical and Experimental Dermatology” Spironolactone reduces pain and lesions in hidradenitis suppurativa patients.
41 citations
,
May 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” The guideline recommends using specific drugs and surgery together for treating hidradenitis suppurativa effectively.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2011 in “Medical Journal of Tabriz University of Medical Sciences and Health Services” Many patients with Alopecia Areata have underlying autoimmune disorders, especially thyroid issues.
July 2024 in “The Egyptian Journal of Hospital Medicine” Serum calprotectin is not a reliable marker for alopecia areata activity.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
April 2024 in “Research Square” IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.
1 citations
,
May 2024 in “Italian Journal of Dermatology and Venereology” Alopecia areata is hard to manage and affects quality of life.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
March 2014 in “Journal of The American Academy of Dermatology” Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
8 citations
,
October 2014 in “The Journal of Dermatology” Patients with alopecia areata should be checked for muscle spasms, diarrhea, and ANA to avoid missing Satoyoshi syndrome.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
2 citations
,
April 2024 in “Journal of International Medical Research” Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
August 2025 in “Clinical and Experimental Dermatology” Alopecia areata treatments often don't lead to lasting improvement.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
1 citations
,
January 2023 in “Annals of Dermatology” The BASP classification helps predict patient behavior and improve treatment for hair loss.